Enovis vs Envista
ENOV and NVST side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENOV and NVST compare
Envista is the larger company, worth 2.5 times as much as Enovis ($3.9B against $1.6B).
Envista grew revenue faster over the last twelve months (9.8% versus 3.3% for Enovis).
Envista keeps more of each dollar of sales as profit, with a net margin of 22.0% compared with −22.9% at Enovis.
Envista scores higher on the StockData Score (17 against 7 for Enovis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENOV | NVST |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $3.9B |
| Share price | $27.68 | $24.49 |
| Change, 1 year | −11.4% | 21.7% |
| Change, 5 years | −81.7% | −41.8% |
| Beta (5Y) | 1.14 | 0.94 |
| Employees | 7,802 | 12K |
| StockData Score | ||
| Total score | 7 | 17 (better) |
| Valuation score | 2 | 6 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 5 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 6.3× |
| P/S | 0.7× (better) | 1.4× |
| P/B | 1.1× (better) | 1.3× |
| EV/EBITDA | 3.3× (better) | 5.0× |
| P/FCF | 22.9× | 16.3× (better) |
| FCF yield | 4.4% | 6.2% (better) |
| Fair value | – | $94.47 |
| Margin of safety | – | 74.1% |
| Growth | ||
| Revenue growth (TTM) | 3.3% | 9.8% (better) |
| Revenue growth, 5Y average | 14.9% (better) | 7.1% |
| Net income growth (TTM) | – | 4041% |
| EPS growth (TTM) | – | 4200% |
| EPS growth, 5Y average | – | 7.0% |
| Profitability | ||
| Gross margin | 61.3% (better) | 55.9% |
| Operating margin | −20.6% | 25.4% (better) |
| Net margin | −22.9% | 22.0% (better) |
| FCF margin | 3.0% | 8.4% (better) |
| Return on equity | −30.0% | 20.5% (better) |
| Return on invested capital | −12.3% | 20.0% (better) |
| Financial health | ||
| Debt / equity | 0.84 | 0.46 (better) |
| Net debt / EBITDA | 1.43 | 0.32 (better) |
| Interest coverage | −14.7× | – |
| Current ratio | 2.15 | 2.45 (better) |
| Altman Z-score | 0.29 | 2.17 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.5% |
| Shareholder yield | 0.00% | 3.5% (better) |
| Ownership | ||
| Held by institutions | 122% | 118% |
| Held by insiders | 2.7% | 0.85% |
| Insider net buying, 12 months | $792K (better) | −$510K |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 18.8% | 6.1% |
Go deeper
- ENOV stock overview
- ENOV income statement
- ENOV valuation and score
- NVST stock overview
- NVST income statement
- NVST valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.